Although the use of hormone replacement therapy for menopause based on estrogens alone increases endometrial cancer risk, several studies indicate that combined therapy with estrogens and progestins is not related to an appreciable excess of endometrial cancer risk, if progestins are given for more than 10 or 14 days in each cycle. Combined therapy, however, may be associated to greater excess in breast cancer incidence as compared to estrogens alone.
Estrogeni e progestinici nella terapia ormonale sostitutiva in menopausa / C. La Vecchia. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 92:3(2001), pp. 209-212.
Estrogeni e progestinici nella terapia ormonale sostitutiva in menopausa
C. La VecchiaPrimo
2001
Abstract
Although the use of hormone replacement therapy for menopause based on estrogens alone increases endometrial cancer risk, several studies indicate that combined therapy with estrogens and progestins is not related to an appreciable excess of endometrial cancer risk, if progestins are given for more than 10 or 14 days in each cycle. Combined therapy, however, may be associated to greater excess in breast cancer incidence as compared to estrogens alone.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
